What is Lanreotide?

A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.

Lanreotide in the library · · Human Trials · What are peptides?

84 registered trials · 226 indexed papers · 249 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.

Type: Somatostatin analog peptide.

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Lanreotide is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (84)

Trial	Phase	Status	Year	Enrolled
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors	Phase 3	recruiting	2025	166
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula	Phase 3	recruiting	2025	274
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands		completed	2023	102
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients	Phase 4	recruiting	2023	270
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy	Phase 3	active not recruiting	2022	343
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	Phase 1	terminated	2022	19
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET	Phase 3	active not recruiting	2021	332
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors	Phase 1/Phase 2	recruiting	2021	49
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs		completed	2021	71
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs	Phase 3	completed	2021	43
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET	Phase 2	unknown	2020	69
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome	Phase 3	withdrawn	2020
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)	Phase 2	active not recruiting	2019	10
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands	Phase 2	completed	2019	39
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula	Phase 2	completed	2018	114
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma	Phase 3	unknown	2018	90
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide	Phase 4	completed	2017	51
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres	Phase 2	terminated	2017	6
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors	Phase 1/Phase 2	completed	2017	22
Efficacy and Safety of Lanreotide Autogel/ Depot [amount hidden] vs. Placebo in Subjects With Lung Neuroendocrine Tumours	Phase 3	terminated	2017	77
The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research		recruiting	2017	1965
Lanreotide in the Treatment of Small Bowel Motility Disorders	Phase 2	completed	2017	12
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET	Phase 4	unknown	2017	28
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors	Phase 2	completed	2016	43
The MetNET-2 Trial	EARLY_Phase 1	unknown	2016	20
Circulating Tumor Cells and Tumor DNA in HCC and NET		completed	2016	167
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.	Phase 2	completed	2016	40
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)	Phase 2/Phase 3	terminated	2015	53
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® [amount hidden]	Phase 2	completed	2015	99
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction	Phase 2	terminated	2015	43
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly	Phase 1/Phase 2	completed	2015	28
Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study	Phase 3	terminated	2015	19
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues	Phase 2	completed	2015	35
Lanreotide In Polycystic Kidney Disease Study	Phase 3	completed	2014	159
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	Phase 4	completed	2014	50
Combination of Lanreotide Autogel [amount hidden] and Temozolomide in Progressive GEP-NET	Phase 2	completed	2014	57
Study to Assess Efficacy and Safety of Lanreotide Autogel [amount hidden] in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction	Phase 2	completed	2014	52
Efficacy and Safety of Lanreotide Autogel® [amount hidden] With Lanreotide [amount hidden] Prolonged Release (PR) in Acromegaly	Phase 3	completed	2014	128
Predictive Factors Study		terminated	2014	5
Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy	Phase 2	unknown	2014	10

Peer-reviewed studies (226)

Paper	Authors	Journal	Year	Type
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study	Charles J et al.	Cancer medicine	2026	Clinical Trial, Phase II
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease	Joly D et al.	Kidney international	2026	Randomized Controlled Trial
[Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT]	Núñez-Martínez FJ et al.	Revista medica del Instituto Mexicano del Seguro Social	2026	Observational Study
Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada	Rayson D et al.	Neuroendocrinology	2026	Observational Study
Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotide	Quock TP et al.	Journal of comparative effectiveness research	2025	Observational Study
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)	Morse MA et al.	Journal of neuroendocrinology	2025	Clinical Trial, Phase II
Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial	Timmer AS et al.	Alimentary pharmacology & therapeutics	2024	Randomized Controlled Trial
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	Baudin E et al.	Endocrine-related cancer	2024	Randomized Controlled Trial
Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine	Gadelha MR et al.	The Journal of clinical endocrinology and metabolism	2024	Randomized Controlled Trial
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study	Pavel M et al.	The oncologist	2024	Randomized Controlled Trial
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2	Pusceddu S et al.	Journal of hematology & oncology	2023	Clinical Trial, Phase I
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial	Corti F et al.	BMC cancer	2023	Clinical Study
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study	Ferolla P et al.	Neuroendocrinology	2023	Clinical Trial, Phase II
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study	Lepage C et al.	European journal of cancer (Oxford, England : 1990)	2022	Randomized Controlled Trial
A phase II trial of lanreotide for the prevention of postoperative pancreatic fistula	Pillarisetty VG et al.	HPB : the official journal of the International Hepato Pancreato Biliary Association	2022	Clinical Trial, Phase II
A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors	Raj N et al.	JCO oncology practice	2022	Randomized Controlled Trial
Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study	Duck L et al.	Clinical therapeutics	2021	Clinical Trial, Phase II
Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study	Bolanowski M et al.	Endokrynologia Polska	2021	Observational Study
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results	Pavel M et al.	European journal of cancer (Oxford, England : 1990)	2021	Clinical Trial, Phase II
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria	Rinke A et al.	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association	2021	Observational Study
Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan	Shimatsu A et al.	Endocrine journal	2021	Clinical Trial, Phase III
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland	Störmann S et al.	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association	2021	Observational Study
Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open-label extension study	Ito T et al.	Asia-Pacific journal of clinical oncology	2021	Clinical Trial, Phase II
Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone	Mesli Y et al.	Journal of investigative surgery : the official journal of the Academy of Surgical Research	2021	Randomized Controlled Trial
Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study)	Shimoyama R et al.	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]	2020	Clinical Study
Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial	Bonert V et al.	The Journal of clinical endocrinology and metabolism	2020	Randomized Controlled Trial
Effectiveness of lanreotide autogel [amount hidden] at extended dosing intervals for acromegaly	Bernabéu I et al.	Endocrine	2020	Observational Study
Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly	Losa M et al.	The Journal of clinical endocrinology and metabolism	2020	Observational Study
Efficacy and safety of lanreotide autogel compared with lanreotide [amount hidden] prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)	An Z et al.	BMC endocrine disorders	2020	Clinical Trial, Phase III
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study	Colao A et al.	European journal of endocrinology	2020	Randomized Controlled Trial

More cited research

Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gla (2001, human observational)
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients (1998, human observational)
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT (None, human trial (non-randomized))
A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly (None, human RCT)

Conditions researched

Related compounds

FAQ

What is Lanreotide?

A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.

How many registered human trials study Lanreotide?

The PeptideWhiz trial index lists 84 registered trials for Lanreotide, the most recent from 2025.

How much published research exists on Lanreotide?

The PeptideWhiz paper index links 226 PubMed papers to Lanreotide; by study type, 249 human and 0 animal studies.

Which conditions is Lanreotide researched for?

Acid reflux and GERD, Eyes: macular degeneration & retinal health, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Gallbladder and gallstones, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Muscle gain, sarcopenia & building muscle after 40, Pancreatitis (after the acute phase), Post-surgical inflammation and surgery recovery, Sleep problems (incl. insomnia on peptides), Thyroid problems.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research